Skip to main content
SpringerLink
Log in

p53 in the Clinic: A Pathologist’s View

  • Chapter
  • First Online:
p53 in the Clinics

  • 1031 Accesses

Abstract

The p53 protein has many biological effects and a high prevalence of mutations in human cancer. Pathologists use this biomarker in several different situations, to help for the differential diagnosis of reactive/dysplastic/benign/malignant lesions, to better characterize malignant tumours, and to help in predicting response to treatment. p53 status of dysplastic and borderline lesions can most often be assessed only by immunohistochemistry (IHC) since these microscopical lesions are too small for advanced molecular assays. p53 protein status determined by IHC has however a smaller sensitivity compared to TP53 status assessed by gene sequencing. This explains why p53 as a biomarker remains not so widely used by pathologists except for several well-defined indications detailed in this chapter. P63, a member of the p53 family, is also frequently used in diagnostic pathology as a differentiation marker and will be discussed in this chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Ali TZ, Epstein JI (2008) False positive labeling of prostate cancer with high molecular weight cytokeratin: p63 a more specific immunomarker for basal cells. Am J Surg Pathol 32:1890–1895

    Article  PubMed  Google Scholar 

  • Al-Maghraby H, Ghorab Z, Khalbuss W, Wong J, Silverman JF, Saad RS (2010) The diagnostic utility of CK5/6 and p63 in fine-needle aspiration of the breast lesions diagnosed as proliferative fibrocystic lesion. Diagn Cytopathol 40(2):141–147

    Article  PubMed  Google Scholar 

  • Alsner J, Jensen V, Kyndi M, Offersen BV, Vu P, Børresen-Dale AL, Overgaard J (2008) A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients. Acta Oncol 47:600–607

    Article  PubMed  CAS  Google Scholar 

  • Amin MB (2010) The 2009 version of the cancer protocols of the college of American pathologists. Arch Pathol Lab Med 134:326–330

    PubMed  Google Scholar 

  • Baas IO, Mulder JW, Offerhaus GJ, Vogelstein B, Hamilton SR (1994) An evaluation of six ­antibodies for immunohistochemistry of mutant TP53 gene product in archival colorectal ­neoplasms. J Pathol 172:5–12

    Article  PubMed  CAS  Google Scholar 

  • Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, Palacios J, Rakha EA, Richardson AL, Schmitt FC, Tan PH, Tse GM, Weigelt B, Ellis IO, Reis-Filho JS (2010) Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol 24(2):157–167

    Article  PubMed  Google Scholar 

  • Bani-Hani K, Martin IG, Hardie LJ, Mapstone N, Briggs JA, Forman D, Wild CP (2000) Prospective study of cyclin D1 overexpression in Barrett’s esophagus: association with increased risk of adenocarcinoma. J Natl Cancer Inst 92:1316–1321

    Article  PubMed  CAS  Google Scholar 

  • Barbareschi M, Pecciarini L, Cangi MG, Macrì E, Rizzo A, Viale G, Doglioni C (2001) p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am J Surg Pathol 25:1054–1060

    Article  PubMed  CAS  Google Scholar 

  • Bártek J, Bártková J, Lukás J, Stasková Z, Vojtĕsek B, Lane DP (1993) Immunohistochemical analysis of the p53 oncoprotein on paraffin sections using a series of novel monoclonal antibodies. J Pathol 169:27–34

    Article  PubMed  Google Scholar 

  • Berggren P, Steineck G, Adolfsson J, Hansson J, Jansson O, Larsson P, Sandstedt B, Wijkström H, Hemminki K (2001) p53 mutations in urinary bladder cancer. Br J Cancer 84:1505–1511

    Article  PubMed  CAS  Google Scholar 

  • Bernardini S, Adessi GL, Billerey C, Chezy E, Carbillet JP, Bittard H (1999) Immunohistochemical detection of p53 protein overexpression versus gene sequencing in urinary bladder carcinomas. J Urol 162:1496–1501

    Article  PubMed  CAS  Google Scholar 

  • Bertheau P, Plassa F, Espié M, Turpin E, de Roquancourt A, Marty M, Lerebours F, Beuzard Y, Janin A, de Thé H (2002) Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet 360:852–854

    Article  PubMed  CAS  Google Scholar 

  • Bertheau P, Lerebours F, Mounier N, de Roquancourt A, Espié M, Clot P, Servant JM, Misset JL, Marty M, Janin A (2005) Prognostic significance of a combined clinicopathologic score for response to primary systemic therapy in locally advanced breast cancer. Oncol Rep 14:513–520

    PubMed  Google Scholar 

  • Bertheau P, Turpin E, Rickman DS, Espié M, de Reyniès A, Feugeas JP, Plassa LF, Soliman H, Varna M, de Roquancourt A, Lehmann-Che J, Beuzard Y, Marty M, Misset JL, Janin A, de Thé H (2007) Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med 4:e90

    Article  PubMed  Google Scholar 

  • Bevilacqua G, Bosman F, Dassesse T, Höfler H, Janin A, Langer R, Larsimont D, Morente MM, Riegman P, Schirmacher P, Stanta G, Zatloukal K, Caboux E, Hainaut P (2010) The role of the pathologist in tissue banking: European Consensus Expert Group Report. Virchows Arch 456:449–454

    Article  PubMed  Google Scholar 

  • Brambilla E, Gazzeri S, Lantuejoul S, Coll JL, Moro D, Negoescu A, Brambilla C (1998) p53 mutant immunophenotype and deregulation of p53 transcription pathway (Bcl2, Bax, and Waf1) in precursor bronchial lesions of lung cancer. Clin Cancer Res 4:1609–1618

    PubMed  CAS  Google Scholar 

  • Bratthauer GL, Saenger JS, Strauss BL (2005) Antibodies targeting p63 react specifically in the cytoplasm of breast epithelial cells exhibiting secretory differentiation. Histopathology 47:611–616

    Article  PubMed  CAS  Google Scholar 

  • Choi SW, Levine JE, Ferrara JL (2010) Pathogenesis and management of graft-versus-host disease. Immunol Allergy Clin North Am 30:75–101

    Article  PubMed  Google Scholar 

  • Coggi G, Bosari S, Roncalli M, Graziani D, Bossi P, Viale G, Buffa R, Ferrero S, Piazza M, Blandamura S, Segalin A, Bonavina L, Peracchia A (1997) p53 protein accumulation and TP53 gene mutation in esophageal carcinoma. A molecular and immunohistochemical study with clinicopathologic correlations. Cancer 79:425–432

    Article  PubMed  CAS  Google Scholar 

  • Colomer A, Erill N, Verdú M, Roman R, Vidal A, Cordon-Cardo C, Puig X (2003) Lack of p53 nuclear immunostaining is not indicative of absence of TP53 gene mutations in colorectal adenocarcinomas. Appl Immunohistochem Mol Morphol 11:130–137

    Article  PubMed  CAS  Google Scholar 

  • de Moraes Schenka NG, Schenka AA, de Souza QL, de Almeida MM, Alvarenga M, Vassallo J (2006) p63 and CD10: reliable markers in discriminating benign sclerosing lesions from tubular carcinoma of the breast? Appl Immunohistochem Mol Morphol 14:71–77

    Article  PubMed  Google Scholar 

  • Di Como CJ, Urist MJ, Babayan I, Drobnjak M, Hedvat CV, Teruya-Feldstein J, Pohar K, Hoos A, Cordon-Cardo C (2002) p63 expression profiles in human normal and tumor tissues. Clin Cancer Res 8:494–501

    PubMed  Google Scholar 

  • Dookeran KA, Dignam JJ, Ferrer K, Sekosan M, McCaskill-Stevens W, Gehlert S (2010) p53 as a marker of prognosis in African-American women with breast cancer. Ann Surg Oncol 17:1398–1405

    Article  PubMed  Google Scholar 

  • Eady RA, Cowen T (1977) Epidermal repair in lichen planus: a light and electron microscopical study. Clin Exp Dermatol 2:323–334

    Article  PubMed  CAS  Google Scholar 

  • Fayallah EA, Hemida RA, Gamal AM, Abd Elhady E, Anwar KI, Nada NA, Sherif LS, Sayed-Ahmed MT (2010) Pretreatment study of P53 overexpression for selection of candidates for pelvic lymphadenectomy in clinical stage I endometrial carcinoma: a randomized-controlled study. Arch Gynecol Obstet 283(3):617–622

    Article  PubMed  Google Scholar 

  • Ferrer-Luna R, Núñez L, Piquer J, Arias E, Dasí F, Cervio A, Arakaki N, Sevlever G, Celda B, Martinetto H (2010) Whole-genomic survey of oligodendroglial tumors: correlation between allelic imbalances and gene expression profiles. J Neurooncol 103(1):71–85

    Article  PubMed  Google Scholar 

  • Fléjou JF, Svrcek M (2007) Barrett’s oesophagus – a pathologist’s view. Histopathology 50:3–14

    Article  PubMed  Google Scholar 

  • Garg K, Leitao MM Jr, Wynveen CA, Sica GL, Shia J, Shi W, Soslow RA (2010) p53 overexpression in morphologically ambiguous endometrial carcinomas correlates with adverse clinical outcomes. Mod Pathol 23:80–92

    Article  PubMed  CAS  Google Scholar 

  • Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, Buchholz T, Meric F, Middleton L, Hortobagyi GN, Gonzalez-Angulo AM (2006) Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 24:1037–1044

    Article  PubMed  Google Scholar 

  • Hamelin R, Fléjou JF, Muzeau F, Potet F, Laurent-Puig P, Fékété F, Thomas G (1994) TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett’s esophagus. Gastroenterology 107:1012–1018

    PubMed  CAS  Google Scholar 

  • Harpaz N, Polydorides AD (2010) Colorectal dysplasia in chronic inflammatory bowel disease: pathology, clinical implications, and pathogenesis. Arch Pathol Lab Med 134:876–895

    PubMed  Google Scholar 

  • Harton AM, Wang HH, Schnitt SJ, Jacobs TW (2007) p63 immunocytochemistry improves accuracy of diagnosis with fine-needle aspiration of the breast. Am J Clin Pathol 128:80–85

    Article  PubMed  Google Scholar 

  • Hodges KB, Lopez-Beltran A, Davidson DD, Montironi R, Cheng L (2010) Urothelial dysplasia and other flat lesions of the urinary bladder: clinicopathologic and molecular features. Hum Pathol 41:155–162

    Article  PubMed  Google Scholar 

  • Horne GM, Anderson JJ, Tiniakos DG, McIntosh GG, Thomas MD, Angus B, Henry JA, Lennard TW, Horne CH (1996) p53 protein as a prognostic indicator in breast carcinoma: a comparison of four antibodies for immunohistochemistry. Br J Cancer 73:29–35

    Article  PubMed  CAS  Google Scholar 

  • Ip PP, Cheung AN, Clement PB (2009) Uterine smooth muscle tumors of uncertain malignant potential (STUMP): a clinicopathologic analysis of 16 cases. Am J Surg Pathol 33:992–1005

    Article  PubMed  Google Scholar 

  • Jacquemier J, Molès JP, Penault-Llorca F, Adélaide J, Torrente M, Viens P, Birnbaum D, Theillet C (1994) p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. Br J Cancer 69:846–852

    Article  PubMed  CAS  Google Scholar 

  • Janin A, Murata H, Leboeuf C, Cayuela JM, Gluckman E, Legrès L, Desveaux A, Varna M, Ratajczak P, Soulier J, de Thé H, Bertheau P, Socié G (2009) Donor-derived oral squamous cell carcinoma after allogeneic bone marrow transplantation. Blood 113:1834–1840

    Article  PubMed  CAS  Google Scholar 

  • Janin-Mercier A, Saurat JH, Bourges M, Sohier J, Jean LD, Gluckman E (1981) The lichen planus like and sclerotic phases of the graft versus host disease in man: an ultrastructural study of six cases. Acta Derm Venereol 61:187–193

    PubMed  CAS  Google Scholar 

  • Jankowski JA, Odze RD (2009) Biomarkers in gastroenterology: between hope and hype comes histopathology. Am J Gastroenterol 104:1093–1096

    Article  PubMed  CAS  Google Scholar 

  • Jia L, Liu Y, Yi X, Miron A, Crum CP, Kong B, Zheng W (2008) Endometrial glandular dysplasia with frequent TP53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma. Clin Cancer Res 14:2263–2269

    Article  PubMed  CAS  Google Scholar 

  • Kaye PV, Haider SA, Ilyas M, James PD, Soomro I, Faisal W, Catton J, Parsons SL, Ragunath K (2009) Barrett’s dysplasia and the Vienna classification: reproducibility, prediction of progression and impact of consensus reporting and p53 immunohistochemistry. Histopathology 54:699–712

    Article  PubMed  Google Scholar 

  • Kaye PV, Haider SA, James PD, Soomro I, Catton J, Parsons SL, Ragunath K, Ilyas M (2010) Novel staining pattern of p53 in Barrett’s dysplasia–the absent pattern. Histopathology 57:933–935

    Article  PubMed  Google Scholar 

  • Keller U, von Bubnoff N, Peschel C, Duyster J (2010) Oncologist’s/haematologist’s view on the roles of pathologists for molecular targeted cancer therapy. J Cell Mol Med 14:805–817

    Article  PubMed  CAS  Google Scholar 

  • Keswani RN, Noffsinger A, Waxman I, Bissonnette M (2006) Clinical use of p53 in Barrett’s esophagus. Cancer Epidemiol Biomarkers Prev 15:1243–1249

    Article  PubMed  CAS  Google Scholar 

  • Khoury MP, Bourdon JC (2010) The isoforms of the p53 protein. Cold Spring Harb Perspect Biol 2:a000927

    Article  PubMed  Google Scholar 

  • Kohno H, Hiroshima K, Toyozaki T, Fujisawa T, Ohwada H (1999) p53 mutation and allelic loss of chromosome 3p, 9p of preneoplastic lesions in patients with nonsmall cell lung carcinoma. Cancer 85:341–347

    Article  PubMed  CAS  Google Scholar 

  • Lambkin HA, Mothersill CM, Kelehan P (1994) Variations in immunohistochemical detection of p53 protein overexpression in cervical carcinomas with different antibodies and methods of detection. J Pathol 172:13–18

    Article  PubMed  CAS  Google Scholar 

  • Lee EJ, Kim TJ, Kim DS, Choi CH, Lee JW, Lee JH, Bae DS, Kim BG (2010) p53 alteration independently predicts poor outcomes in patients with endometrial cancer: a clinicopathologic study of 131 cases and literature review. Gynecol Oncol 116:533–538

    Article  PubMed  CAS  Google Scholar 

  • Lehmann-Che J, André F, Desmedt C, Mazouni C, Giacchetti S, Turpin E, Espié M, Plassa LF, Marty M, Bertheau P, Sotiriou C, Piccart M, Symmans WF, Pusztai L, de Thé H (2010) Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers. Oncologist 15:246–252

    Article  PubMed  CAS  Google Scholar 

  • Levine AJ, Oren M (2009) The first 30 years of p53: growing ever more complex. Nat Rev Cancer 9:749–758

    Article  PubMed  CAS  Google Scholar 

  • Loo PS, Thomas SC, Nicolson MC, Fyfe MN, Kerr KM (2010) Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol 5:442–447

    Article  PubMed  Google Scholar 

  • Louis DN (1994) The TP53 gene and protein in human brain tumors. J Neuropathol Exp Neurol 53:11–21

    Article  PubMed  CAS  Google Scholar 

  • Malats N, Bustos A, Nascimento CM, Fernandez F, Rivas M, Puente D, Kogevinas M, Real FX (2005) P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 6:678–686

    Article  PubMed  CAS  Google Scholar 

  • Marx A, Wandrey T, Simon P, Wewer A, Grob T, Reichelt U, Minner S, Simon R, Spehlmann M, Tigges W, Soehendra N, Seitz U, Seewald S, Izbicki JR, Yekebas E, Kaifi JT, Mirlacher M, Terracciano L, Fleischmann A, Raedler A, Sauter G (2009) Combined alpha-methylacyl coenzyme A racemase/p53 analysis to identify dysplasia in inflammatory bowel disease. Hum Pathol 40:166–173

    Article  PubMed  CAS  Google Scholar 

  • Molinié V, Fromont G, Sibony M, Vieillefond A, Vassiliu V, Cochand-Priollet B, Hervé JM, Lebret T, Baglin AC (2004) Diagnostic utility of a p63/alpha-methyl-CoA-racemase (p504s) cocktail in atypical foci in the prostate. Mod Pathol 17:1180–1190

    Article  PubMed  Google Scholar 

  • Nenutil R, Smardova J, Pavlova S, Hanzelkova Z, Muller P, Fabian P, Hrstka R, Janotova P, Radina M, Lane DP, Coates PJ, Vojtesek B (2005) Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. J Pathol 207:251–259

    Article  PubMed  CAS  Google Scholar 

  • Nicholson AG, Gonzalez D, Shah P, Pynegar MJ, Deshmukh M, Rice A, Popat S (2010) Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. J Thorac Oncol 5:436–441

    Article  PubMed  Google Scholar 

  • Odze RD (2006) Diagnosis and grading of dysplasia in Barrett’s oesophagus. J Clin Pathol 59:1029–1038

    Article  PubMed  CAS  Google Scholar 

  • Odze RD, Riddell RH, Bosman FT, Carneiro F, Fléjou J-F, Geboes K et al (2010) Premalignant lesions of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (eds) WHO classification of tumours of digestive system. IARC, Lyon

    Google Scholar 

  • Okamoto Y, Di Patre PL, Burkhard C, Horstmann S, Jourde B, Fahey M, Schüler D, Probst-Hensch NM, Yasargil MG, Yonekawa Y, Lütolf UM, Kleihues P, Ohgaki H (2004) Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol 108:49–56

    Article  PubMed  Google Scholar 

  • Osamura RY (2009) Roles of pathologists in molecular targeted cancer therapy. J Cell Mol Med 13:4286–4290

    Article  PubMed  CAS  Google Scholar 

  • Peraud A, Kreth FW, Wiestler OD, Kleihues P, Reulen HJ (2002) Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas. Clin Cancer Res 8:1117–1124

    PubMed  CAS  Google Scholar 

  • Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406:747–752

    Article  PubMed  CAS  Google Scholar 

  • Pezzella F, Micklem K, Turley H, Pulford K, Jones M, Kocialkowski S, Delia D, Aiello A, Bicknell R, Smith K (1994) Antibody for detecting p53 protein by immunohistochemistry in normal tissues. J Clin Pathol 47:592–596

    Article  PubMed  CAS  Google Scholar 

  • Pfaff E, Remke M, Sturm D, Benner A, Witt H, Milde T, von Bueren AO, Wittmann A, Schöttler A, Jorch N, Graf N, Kulozik AE, Witt O, Scheurlen W, von Deimling A, Rutkowski S, Taylor MD, Tabori U, Lichter P, Korshunov A, Pfister SM (2010) TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. J Clin Oncol 28:5188–5196

    Article  PubMed  CAS  Google Scholar 

  • Ponticiello A, Barra E, Giani U, Bocchino M, Sanduzzi A (2000) P53 immunohistochemistry can identify bronchial dysplastic lesions proceeding to lung cancer: a prospective study. Eur Respir J 15:547–552

    Article  PubMed  CAS  Google Scholar 

  • Prasad GA, Bansal A, Sharma P, Wang KK (2010) Predictors of progression in Barrett’s esophagus: current knowledge and future directions. Am J Gastroenterol 105:1490–1502

    Article  PubMed  Google Scholar 

  • Quddus MR, Sung CJ, Zheng W, Lauchlan SC (1999) p53 immunoreactivity in endometrial metaplasia with dysfunctional uterine bleeding. Histopathology 35:44–49

    Article  PubMed  CAS  Google Scholar 

  • Reis-Filho JS, Milanezi F, Amendoeira I, Albergaria A, Schmitt FC (2002) p63 Staining of myoepithelial cells in breast fine needle aspirates: a study of its role in differentiating in situ from invasive ductal carcinomas of the breast. J Clin Pathol 55:936–939

    Article  PubMed  CAS  Google Scholar 

  • Renninson J, Baker BW, McGown AT, Murphy D, Norton JD, Fox BW, Crowther D (1994) Immunohistochemical detection of mutant p53 protein in epithelial ovarian cancer using polyclonal antibody CMI: correlation with histopathology and clinical features. Br J Cancer 69:609–612

    Article  PubMed  CAS  Google Scholar 

  • Ribeiro-Silva A, Ramalho LN, Garcia SB, Brandão DF, Chahud F, Zucoloto S (2005) p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer. Histopathology 47:458–466

    Article  PubMed  CAS  Google Scholar 

  • Riddell RH, Goldman H, Ransohoff DF, Appelman HD, Fenoglio CM, Haggitt RC, Ahren C, Correa P, Hamilton SR, Morson BC (1983) Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 14:931–968

    Article  PubMed  CAS  Google Scholar 

  • Rodriguez FJ, Scheithauer BW, Burger PC, Jenkins S, Giannini C (2010) Anaplasia in pilocytic astrocytoma predicts aggressive behavior. Am J Surg Pathol 34:147–160

    Article  PubMed  Google Scholar 

  • Saurat JH, Gluckman E (1977) Lichen-planus-like eruption following bone marrow transplantation: a manifestation of the graft-versus-host disease. Clin Exp Dermatol 2:335–344

    PubMed  CAS  Google Scholar 

  • Shah RB, Zhou M, LeBlanc M, Snyder M, Rubin MA (2002) Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer. Am J Surg Pathol 26:1161–1168

    Article  PubMed  Google Scholar 

  • Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, Yang A, Montironi R, McKeon F, Loda M (2000) p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 157:1769–1775

    Article  PubMed  CAS  Google Scholar 

  • Sikkema M, Kerkhof M, Steyerberg EW, Kusters JG, van Strien PM, Looman CW, van Dekken H, Siersema PD, Kuipers EJ (2009) Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett’s esophagus: a case–control study. Am J Gastroenterol 104:2673–2680

    Article  PubMed  CAS  Google Scholar 

  • Socié G, Henry-Amar M, Bacigalupo A, Hows J, Tichelli A, Ljungman P, McCann SR, Frickhofen N, Van’t Veer-Korthof E, Gluckman E (1993) Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. N Engl J Med 329:1152–1157

    Article  PubMed  Google Scholar 

  • Soong R, Robbins PD, Dix BR, Grieu F, Lim B, Knowles S, Williams KE, Turbett GR, House AK, Iacopetta BJ (1996) Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Hum Pathol 27:1050–1055

    Article  PubMed  CAS  Google Scholar 

  • Sozzi G, Miozzo M, Donghi R, Pilotti S, Cariani CT, Pastorino U, Della Porta G, Pierotti MA (1992) Deletions of 17p and TP53 mutations in preneoplastic lesions of the lung. Cancer Res 52:6079–6082

    PubMed  CAS  Google Scholar 

  • Spruck CH, Ohneseit PF, Gonzalez-Zulueta M, Esrig D, Miyao N, Tsai YC, Lerner SP, Schmütte C, Yang AS, Cote R (1994) Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 54:784–788

    PubMed  CAS  Google Scholar 

  • Ständer M, Peraud A, Leroch B, Kreth FW (2004) Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis. Cancer 101:1028–1035

    Article  PubMed  Google Scholar 

  • Stiewe T (2007) The p53 family in differentiation and tumorigenesis. Nat Rev Cancer 7:165–168

    Article  PubMed  CAS  Google Scholar 

  • Sun W, Zhang PL, Herrera GA (2002) p53 protein and Ki-67 overexpression in urothelial dysplasia of bladder. Appl Immunohistochem Mol Morphol 10:327–331

    Article  PubMed  CAS  Google Scholar 

  • Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:466–475, discussion 475–477

    Article  PubMed  Google Scholar 

  • Tabori U, Baskin B, Shago M, Alon N, Taylor MD, Ray PN, Bouffet E, Malkin D, Hawkins C (2010a) Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. J Clin Oncol 28:1345–1350

    Article  PubMed  CAS  Google Scholar 

  • Tabori U, Shlien A, Baskin B, Levitt S, Ray P, Alon N, Hawkins C, Bouffet E, Pienkowska M, Lafay-Cousin L, Gozali A, Zhukova N, Shane L, Gonzalez I, Finlay J, Malkin D (2010b) TP53 alterations determine clinical subgroups and survival of patients with choroid plexus tumors. J Clin Oncol 28:1995–2001

    Article  PubMed  CAS  Google Scholar 

  • Tse GM, Tan PH, Moriya T (2009) The role of immunohistochemistry in the differential diagnosis of papillary lesions of the breast. J Clin Pathol 62:407–413

    Article  PubMed  CAS  Google Scholar 

  • Vojtĕsek B, Fisher CJ, Barnes DM, Lane DP (1993) Comparison between p53 staining in tissue sections and p53 proteins levels measured by an ELISA technique. Br J Cancer 67:1254–1258

    Article  PubMed  Google Scholar 

  • Wagner U, Sauter G, Moch H, Novotna H, Epper R, Mihatsch MJ, Waldman FM (1995) Patterns of p53, erbB-2, and EGF-r expression in premalignant lesions of the urinary bladder. Hum Pathol 26:970–978

    Article  PubMed  CAS  Google Scholar 

  • Wang X, Mori I, Tang W, Nakamura M, Nakamura Y, Sato M, Sakurai T, Kakudo K (2002) p63 expression in normal, hyperplastic and malignant breast tissues. Breast Cancer 9:216–219

    Article  PubMed  Google Scholar 

  • Wang W, Sun X, Epstein JI (2008) Partial atrophy on prostate needle biopsy cores: a morphologic and immunohistochemical study. Am J Surg Pathol 32:851–857

    Article  PubMed  Google Scholar 

  • Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J, Westphal M, Schackert G, Simon M, Tonn JC, Heese O, Krex D, Nikkhah G, Pietsch T, Wiestler O, Reifenberger G, von Deimling A, Loeffler M (2009) Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 27:5743–5750

    Article  PubMed  CAS  Google Scholar 

  • Werling RW, Hwang H, Yaziji H, Gown AM (2003) Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain. Am J Surg Pathol 27:82–90

    Article  PubMed  Google Scholar 

  • Wiesend WN, Parasuraman R, Li W, Farinola MA, Rooney MT, Hick SK, Samarapungavan D, Cohn SR, Reddy GH, Rocher LL, Dumler F, Lin F, Zhang PL (2010) Adjuvant role of p53 immunostaining in detecting BK viral infection in renal allograft biopsies. Ann Clin Lab Sci 40:324–329

    PubMed  Google Scholar 

  • Würl P, Taubert H, Meye A, Berger D, Lautenschläger C, Holzhausen HJ, Schmidt H, Kalthoff H, Rath FW, Dralle H (1997) Prognostic value of immunohistochemistry for p53 in primary soft-tissue sarcomas: a multivariate analysis of five antibodies. J Cancer Res Clin Oncol 123:502–508

    Article  PubMed  Google Scholar 

  • Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, Bonnin J, Vagner C, Bonnet H, Dikkes P, Sharpe A, McKeon F, Caput D (2000) p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 404:99–103

    Article  PubMed  CAS  Google Scholar 

  • Zhou M, Shah R, Shen R, Rubin MA (2003) Basal cell cocktail (34betaE12  +  p63) improves the detection of prostate basal cells. Am J Surg Pathol 27:365–371

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We thank our colleagues from several laboratories of pathology who kindly answered our survey: J. Brière, F. Capron, J.M. Coindre, A. Couvelard, J.F. Emile, K. Mokhtari, V. Paradis, M. Peuchmaur, M.C. Vacher-Lavenue, and L. Xerri.

Author information

Authors and Affiliations

  1. Department of Pathology, AP-HP, Hospital Saint-Louis, 1 av C. Vellefaux, 75010, Paris, France

    Philippe Bertheau & Anne Janin

  2. INSERM UMR_S728, Paris, 75010, France

    Philippe Bertheau & Anne Janin

  3. University Paris Diderot – Paris 7, Paris, 75010, France

    Philippe Bertheau, Hugues de Thé, Anne Janin & Jacqueline Lehmann-Che

  4. Department of Pathology, AP-HP, Hospital Saint-Antoine, Paris, France

    Jean-François Fléjou

  5. Faculté de Médecine Pierre et Marie Curie, INSERM UMR_S 938, Centre de Recherche Saint-Antoine, Paris, France

    Jean-François Fléjou

  6. Department of Pathology, AP-HP, Hospital Henri Mondor, Créteil, France

    Yves Allory

  7. Faculté de Médecine, INSERM U955, Institut Mondor de Recherche Biomédicale, Université Paris Est Créteil, Créteil, France

    Yves Allory

  8. Department of Pathology, Hospital Sainte Anne, Paris, France

    Pascale Varlet

  9. Department of Pathology, CHU A Michallon, Grenoble, France

    Sylvie Lantuejoul

  10. INSERM U 823 Institut A Bonniot, Université J Fourier, Grenoble, France

    Sylvie Lantuejoul

  11. Laboratory of Biochemistry, AP-HP, Hospital Saint-Louis, Paris, 75010, France

    Louis-François Plassa, Hugues de Thé & Jacqueline Lehmann-Che

  12. CNRS UMR7212, INSERM U944, Paris, 75010, France

    Hugues de Thé & Jacqueline Lehmann-Che

Authors
  1. Philippe Bertheau
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jean-François Fléjou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yves Allory
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pascale Varlet
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sylvie Lantuejoul
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Louis-François Plassa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hugues de Thé
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Anne Janin
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jacqueline Lehmann-Che
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philippe Bertheau .

Editor information

Editors and Affiliations

  1. International Prevention Research Instit, 95 cours Lafayette, Lyon, 69006, France

    Pierre Hainaut

  2. International Agency for Cancer Research, 150 Cours Albert-Thomas, Lyon, 69372, France

    Magali Olivier

  3. Cancer Center Karolinska (CCK), Dept. Oncology and Pathology, Karolinska Institute, Karolinska Institutet, Stockholm, 171 76, Sweden

    Klas G. Wiman

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Bertheau, P. et al. (2013). p53 in the Clinic: A Pathologist’s View. In: Hainaut, P., Olivier, M., Wiman, K. (eds) p53 in the Clinics. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-3676-8_17

Download citation

Publish with us

Policies and ethics

Search

Navigation